News, background reports, and study updates on the treatment of dry age-related macular degeneration and the MACULIGHT study.
The nationwide MACULIGHT study is the first to investigate the effectiveness of photobiomodulation for home use in dry age-related macular degeneration. An overview of the background, study design, and current state of research.
Read articleThe Amsler grid test is one of the easiest methods to detect changes in central vision early. Instructions, warning signs, and limitations of the self-test.
Read moreThe AREDS2 study by the National Eye Institute proves which vitamins and minerals can slow the progression of AMD. Evidence-based overview of lutein, zeaxanthin, zinc, and the AREDS2 formula.
Read moreWhat is photobiomodulation and how does it affect the retina? An explanatory article about the mechanism of action with 670 nm, the difference to laser, the safety profile, and the current evidence.
Read moreEvidence-based measures for AMD prevention: nutrition, smoking cessation, UV protection, exercise, and regular check-ups. Practical tips for everyday life from 50+.
Read moreStatus report on photobiomodulation for dry AMD: evidence after LIGHTSITE III, FDA authorization of the Valeda system, ongoing studies (MACULIGHT, EUROLIGHT), and the concept of home therapy.
Read moreFour statutory health insurance companies have selected MACULIGHT as a winning innovation in the Healthy Hub 2025 competition. Together with BIG direkt gesund and mhplus, PBM home therapy will be piloted for GKV integration.
Read more